Lacerol Retard

Diltiazem Hydrochloride, the active ingredient in Lacerol Retard, is a calcium channel blocker presented as an extended‑release tablet for oral use. It is indicated for the treatment of hypertension, chronic stable angina, and rate control in atrial fibrillation in adult patients. GNH USA supplies Lacerol Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Diltiazem, a calcium channel blocker, is used in cardiovascular conditions that involve elevated blood pressure or myocardial oxygen demand.

Hypertension: lowers systemic blood pressure by vasodilation and reduced cardiac contractility. Chronic stable angina: decreases frequency of angina attacks by improving coronary blood flow and reducing myocardial oxygen demand. Atrial fibrillation (rate control): slows ventricular rate by decreasing AV‑node conduction.

Adverse reactions may occur with any medication. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Headache - Dizziness or light‑headedness - Flushing - Peripheral edema - Constipation - Nausea

Serious or Rare Side Effects: - Severe bradycardia or heart block - Marked hypotension - Hepatic dysfunction - Life‑threatening allergic reactions (e.g., Stevens‑Johnson syndrome) - Atrioventricular conduction disturbances

Before initiating therapy, several safety considerations are recommended.

Monitor blood pressure regularly: ensure therapeutic effect and avoid hypotension. Assess cardiac function: especially in patients with existing conduction abnormalities. Use caution in hepatic impairment: dose adjustments may be required. Avoid abrupt discontinuation: tapering reduces risk of rebound hypertension. Review concomitant medications affecting heart rate: adjust therapy as needed. Store at ambient temperature: keep in the original pack, protect from moisture.

Diltiazem may interact with several drugs, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Beta‑blockers: increased risk of bradycardia and AV‑block. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): elevated diltiazem plasma levels. - Digoxin: heightened digoxin concentrations and toxicity.

Moderate Interactions (Monitor Closely): - Verapamil or other calcium‑channel blockers: additive cardiac depressant effects. - ACE inhibitors or ARBs: potential for excessive hypotension. - CYP3A4 inducers (e.g., rifampin): reduced diltiazem efficacy.